Pankaj Kumar

Pankaj Kumar

Auto-generated profile, based on publicly available information

Pankaj Kumar

Panjab University, University Institute of Pharmaceutical Sciences, Chandigarh, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2026 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
MPMona Piplani
Mona Piplani
STShivani Thakur
Shivani Thakur
PKPankaj Kumar
Pankaj Kumar
SGSourbh Suren Garg
Sourbh Suren Garg
AGAnkush Goyal
Ankush Goyal
PGPradeep Goyal
Pradeep Goyal
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxidative stress, and genetic influences. While the intricate interplay and individual contributions of these elements to AD progression remain under investigation, considerable advancements have been made in elucidating their roles. This review examines the molecular mechanisms underlying the pathogenesis of AD, highlighting how each factor contributes to the onset and progression of the disorder. To date, significant efforts in AD research have focused on diverse therapeutic approaches, including targeting Aβ and tau proteins, modulating neuroinflammation, enhancing autophagy, and restoring synaptic function. As these strategies evolve, they provide renewed hope for interventions that could slow AD progression and improve cognitive function. Furthermore, a multi-targeted approach addressing these interconnected pathways shows promise for managing the complex pathology of AD. Continued research in these areas will be essential for identifying novel therapeutic options and advancing clinical strategies for AD management.

18 September 2026 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
PKPankaj Kumar
Pankaj Kumar
ZZZahid Bashir Zargar
Zahid Bashir Zargar
SSSuraj Pratap Singh
Suraj Pratap Singh
KKKushvinder Kumar
Kushvinder Kumar
BSBinita Sihag
Binita Sihag
SPSandip Pawar
Sandip Pawar

10 November 2026 in Current Chemical Biology
Verified
Journal Article
Closed access
PKPankaj Kumar
Pankaj Kumar
RRRupali Rana
Rupali Rana
SCShikha Chaudhary
Shikha Chaudhary
SPSwati Pundir
Swati Pundir
SGSourbh Suren Garg
Sourbh Suren Garg
SPSandip Pawar
Sandip Pawar
Introduction: Aloe barbadensis (L.) Miller (Aloe vera) is a widely used ethnomedicinal plant applied for burns, wounds, digestive ailments, and skin disorders. Its therapeutic effects are attributed to bioactive compounds such as anthraquinones, polysaccharides, flavonoids, chromones, vitamins, and minerals. This review critically summarizes recent advances (2018-2025) in the ethnopharmacology, phytochemistry, and pharmacological activities of A. barbadensis. Methods: Relevant literature was retrieved from databases, including PubMed, ScienceDirect, Springer, NCBI, and Google Scholar, with a focus on preclinical and clinical studies. Results: Preclinical evidence demonstrates antimicrobial, anti-inflammatory, antioxidant, anticancer, and wound-healing properties, largely driven by synergistic phytoconstituents. Additional benefits include immune modulation, oxidative stress reduction, and gastrointestinal protection. Clinical studies remain limited, primarily evaluating crude extracts for dermatological and digestive applications. The lack of robust randomized trials and compound-specific investigations limits clinical translation. Discussion: A. barbadensis shows promise as a multi-target therapeutic agent, particularly in inflammation, oxidative stress, and skin health. However, variability in phytochemical composition and insufficient standardization hinder its broader application. Conclusion: While supported by traditional use and preclinical findings, its clinical potential requires validation through well-designed trials, mechanistic studies, and standardized formulations.